the NIH is no longer using Rezulin (troglitazone) in their large Diabetes Prevention Study

The NIH is no longer using Rezulin (troglitazone) in theirlarge Diabetes Prevention Study.

This study is designed to see if type 2 diabetes can beprevented or patients with impaired glucose tolerance.

Researchers were testing 3 treatment and exercise,metformin (Glucophage), and troglitazone (Rezulin).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote